If that does happen, HER2 inhibitor Enhertu could become the ... a lengthening list of indications across breast, gastric, and non-small cell lung cancer (NSCLC), as well as tissue-agnostic ...

for AstraZeneca International's work on an AI collaboration for the early detection of lung cancer. While AZ was the only organisation to take home two prizes, it was certainly in good company.